Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030264 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
A Phase 2 study, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00030264 is a Phase 2 study that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 23 participants.
The verdict
NCT00030264, a Phase 2 study, has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining methotrexate with vinblastine may be effective treatment for neurofibromatosis type 1 associated with progressive plexiform neurofibromas. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have neurofibromatosis type 1 associated with progressive plexiform neurofibromas.
Interventions
- DRUG Methotrexate
- DRUG Vinblastine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2001-02 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00030264
The ClinicalTrials.gov registry entry for NCT00030264 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Methotrexate is the first listed.
NCT00030264 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00030264 about?
NCT00030264 is a clinical study titled "Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining methotrexate with vinblastine may be effective treatment for neurofibromatosis type 1 associated with progressive plexiform neurofibromas. PURPOSE: Phase II trial to stu...
What is the current status of trial NCT00030264?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2001-02. Estimated completion is 2016-03.
What interventions are being tested in trial NCT00030264?
The interventions under investigation include: Methotrexate (DRUG), Vinblastine (DRUG).
Who is sponsoring clinical trial NCT00030264?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.